Atopic dermatitis affects an estimated 10 to 20 percent of children and up to 10 percent of adults globally, with prevalence climbing sharply across Southeast and East Asia over the past decade. When first-line emollients and topical steroids fail, patients move to systemic immunosuppressants: cyclosporine, methotrexate, dupilumab, or JAK inhibitors. Each carries meaningful side-effect burdens or cost barriers. For a growing number of investigators, mesenchymal stromal cells and their secreted extracellular vesicles represent a fundamentally different therapeutic logic: rather than blocking a single cytokine, MSCs modulate the broad inflammatory milieu responsible for epidermal barrier breakdown and pruritus. Two 2025-2026 clinical datasets now give the field its clearest picture yet of where this approach stands.

A 2026 Meta-Analysis: Pooled Data Across Five Clinical Trials

The most comprehensive quantitative assessment to date comes from Cevallos-Cueva et al., who conducted a systematic review and meta-analysis published in Stem Cells and Development in October 2026. They pooled four randomized controlled trials and one non-randomized clinical trial, yielding 236 participants treated with MSCs from human umbilical cord blood, autologous adipose tissue, or allogeneic bone marrow (DOI: 10.1177/15473287261475857).

The headline efficacy numbers:

• EASI-50 at week 12: 46.76% (95% CI: 32.36% to 61.72%)
• EASI-75 at week 12: 17.41% (95% CI: 5.56% to 43.03%)
• EASI-75 at week 16: 23.97% (95% CI: 16.48% to 33.50%)

The pooled incidence of treatment-emergent adverse events was 26.86% (95% CI: 19.56% to 35.68%), with infections and infestations at 7.97% and gastrointestinal disorders at 3.52%. Importantly, the authors note that most adverse events were mild to moderate, and no treatment-related serious adverse events were reported across the pooled trials.

What the meta-analysis lacks, and what the authors are candid about, is large-scale Phase 3 data. The confidence intervals remain wide, particularly for EASI-75 at week 12, reflecting both small sample sizes and heterogeneity in MSC source and dosing protocols. This is a field where the pooled signal is encouraging but the individual trial maturity is insufficient to shift practice guidelines. That said, the EASI-75 response rate of roughly 24 percent at week 16 puts MSC therapy in a range that warrants serious comparison with existing biologics, especially given that no biologic specificity is required from the donor cell product.

The Phase 2 RCT That Moves the Needle

In December 2025, Seok et al. published what is now the largest dedicated RCT of MSC therapy in atopic dermatitis in Stem Cell Research and Therapy (DOI: 10.1186/s13287-025-04763-y). This multicenter, randomized, single-blind, placebo-controlled Phase 2 trial (NCT04137562) enrolled 114 participants with moderate to severe AD refractory to conventional treatment. Patients received two intravenous infusions of autologous adipose-derived MSCs (AtMSCs) or placebo at four-week intervals, with follow-up through 16 weeks.

Key findings:

• EASI total score showed statistically significant improvement versus placebo at weeks 8, 12, and 16 (P = 0.017, 0.015, and < 0.001 respectively).
• At week 16, 23.7% of the treatment group achieved EASI-75 versus 7.3% placebo (P = 0.016).
• SCORAD, Investigator’s Global Assessment, and disease severity scores all favoured the treatment arm.
• TARC/CCL17, a Th2 chemokine biomarker that correlates with AD severity, showed a significant between-group difference at week 16, suggesting MSCs modulate the underlying Th2 axis rather than merely suppressing downstream symptoms.

The EASI-75 rate in the Seok trial aligns closely with the meta-analysis pooled estimate, which strengthens confidence in the signal. At 23.7% versus 23.97% across different MSC sources and trial designs, there is a reproducibility that many early-stage cell therapies fail to demonstrate. That said, the single-blind design is a limitation: double-blind Phase 3 confirmation is explicitly called for by the authors.

Why MSCs Work in AD: Mechanistic Rationale

Atopic dermatitis is primarily a Th2-driven disease, characterised by elevated IL-4, IL-13, IL-31, and TARC/CCL17, along with defective skin barrier proteins (filaggrin, claudin-1). MSCs address this through multiple non-redundant mechanisms:

• Th2 suppression: MSC-derived prostaglandin E2 and indoleamine 2,3-dioxygenase shift the T-cell balance from Th2 to Th1, directly reducing the cytokine drivers of AD.
• Regulatory T-cell induction: MSCs promote Foxp3+ Treg expansion, which provides lasting immunosuppressive memory beyond the transient lifespan of the infused cells themselves.
• Barrier repair: Paracrine factors from MSCs upregulate keratinocyte expression of filaggrin and tight junction proteins, addressing the structural defect that permits allergen penetration.
• Antipruritic effect: MSCs reduce IL-31 expression and downregulate histamine receptor signaling on sensory neurons, a mechanism not addressed by dupilumab or JAK inhibitors.

The Cell-Free Pivot: Exosomes and Hydrogels

A recurring concern with whole-cell MSC therapy is variability in cell quality, donor-to-donor heterogeneity, and manufacturing complexity. Three 2026 studies point toward extracellular vesicles as the more scalable next step.

Zhao et al. in International Immunopharmacology demonstrated that umbilical cord MSC-derived exosomes loaded into a thermosensitive poloxamer hydrogel ameliorated AD in a mouse model (DOI: 10.1016/j.intimp.2026.116297). Their system achieved sustained local release, reduced serum IgE and Th2 cytokines, and produced efficacy comparable to the topical corticosteroid mometasone furoate with a superior safety profile. The hydrogel formulation solved the delivery problem that has plagued systemic exosome administration: poor local bioavailability in the skin.

Kim et al. in Molecular Immunology took a different approach, conditioning donor MSCs with cobalt chloride to induce a hypoxic phenotype before exosome isolation (DOI: 10.1016/j.molimm.2025.12.008). The resulting exosomes had enhanced anti-inflammatory and barrier-repair cargo, outperforming normoxic exosomes in an oxazolone-induced chronic AD model. This hypoxic conditioning strategy is now being applied across multiple indications and may represent a general platform for boosting exosome potency.

A critical quality-control question was addressed by Cho et al. in Stem Cell Research and Therapy (DOI: 10.1186/s13287-026-05104-3). Using multi-omics profiling across three GMP-grade adipose-derived MSC exosome batches from different donors, they demonstrated that functional anti-inflammatory properties, CD73 enzymatic activity, and in vivo efficacy in an AD mouse model were highly consistent between batches. Their argument is that batch-to-batch reproducibility, when guided by bioinformatics-informed quality control rather than single-parameter assays, is achievable for clinical-grade exosome products. This is exactly the kind of manufacturing evidence that regulatory agencies require before approving scalable production.

The Phase 1/2 Bone Marrow MSC Trial

Seo et al. published in Journal of Allergy and Clinical Immunology a Phase 1/2 trial using bone marrow-derived clonal MSCs (PMID: 38944393). These are not donor-heterogeneous bone marrow aspirates but a single cloned MSC line expanded under GMP conditions. The use of a clonal product eliminates donor variability and represents a distinct manufacturing philosophy from the autologous adipose approach of the Seok trial. Safety was the primary endpoint, with efficacy signals that motivated Phase 2 expansion across multiple dermatology centres in South Korea. The cloned BM-MSC strategy is particularly relevant for Asian markets where manufacturing infrastructure for clonal cell banks is advancing rapidly.

Where This Fits in the Treatment Algorithm

Current guidelines for moderate to severe AD run: topical calcineurin inhibitors, systemic cyclosporine or methotrexate, dupilumab, then JAK inhibitors (upadacitinib, baricitinib, abrocitinib). Each step adds immunosuppressive burden or cost. MSC therapy does not slot into any of these positions today, but the evidence base is accumulating toward a future where:

• IV MSC infusion could serve as a steroid-sparing strategy for patients who cycle through multiple systemic agents without sustained control.
• Topical exosome formulations (especially in sustained-release hydrogels) could become adjuncts to standard therapy, particularly for patients with recalcitrant localised disease.
• MSC therapy may offer value for patients who are poor candidates for long-term biologic use due to infection history, hepatic compromise, or cost.

For dermatologists in Thailand and across Southeast Asia, the practical question is when this transitions from clinical trial to clinical availability. The Phase 2 RCT data from Seok et al. and the meta-analysis pooled efficacy provide the evidentiary foundation. The manufacturing consistency data from Cho et al. address the regulatory manufacturing hurdle. What remains is Phase 3 confirmation with double-blind design, proper dosing optimization, and long-term safety follow-up.

Frequently Asked Questions

Is MSC therapy for atopic dermatitis approved anywhere?

No regulatory agency has approved MSC therapy specifically for atopic dermatitis. All published clinical data come from investigational trials. Some countries with expanded access frameworks may permit compassionate use on a case-by-case basis.

How does MSC efficacy compare to dupilumab?

Direct head-to-head data do not exist. Dupilumab achieves EASI-75 rates of roughly 40 to 60 percent at week 16 in most Phase 3 trials, which is higher than the 24 percent seen with MSCs in the pooled analysis. However, MSCs are a single or dual-infusion intervention with a different mechanism, and may suit patients who fail or cannot tolerate biologics. Any comparison must be interpreted cautiously given differences in trial design and patient selection.

What are the side effects?

Across the 236-patient meta-analysis, 26.86% experienced treatment-emergent adverse events, predominantly mild infections (7.97%) and gastrointestinal symptoms (3.52%). No treatment-related serious adverse events were reported. Exosome-based approaches are expected to have even lower immunogenicity, though long-term safety data from exosome trials in AD are not yet available.

Which is better: autologous or allogeneic MSCs?

The Seok trial used autologous adipose-derived MSCs; the Seo trial used an allogeneic bone marrow clonal line; the meta-analysis pooled both sources. There is no definitive comparative data in AD specifically. Autologous cells avoid graft rejection but require a liposuction harvest per patient. Allogeneic products are more scalable but may face faster immune clearance.

When will MSC therapy be available for AD patients in Asia?

Based on the current trial pipeline, Phase 3 trials are likely to begin enrolling in 2027, with regulatory filing possible by 2029 to 2030 if results are positive. In some jurisdictions, clinical trial access is available now. Contact Cell La Vie for the latest information on trial availability and candidacy assessment.

---

References

1. Cevallos-Cueva M, Ghanem L, Novis T, et al. The Potential Role of Mesenchymal Stem Cell Therapy for Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Human Clinical Trials. Stem Cells and Development. 2026;35(19-20):377-385. DOI: 10.1177/15473287261475857
2. Seok J, Kim SY, Lee WG, et al. Efficacy and safety of autologous adipose-derived stem cells in subjects with moderate to severe atopic dermatitis: a multicenter, randomized, single-blind, placebo-controlled, phase 2 trial. Stem Cell Research and Therapy. 2025;16(1):671. DOI: 10.1186/s13287-025-04763-y
3. Seo HM, Lew BL, Lee YW, et al. Phase 1/2 trials of human bone marrow-derived clonal mesenchymal stem cells for treatment of adults with moderate to severe atopic dermatitis. Journal of Allergy and Clinical Immunology. 2024;154(4):965-973. DOI: 10.1016/j.jaci.2024.06.013
4. Zhao X, Zhang Y, Dong Y, et al. Umbilical cord mesenchymal stem cell-derived exosomes delivered via a thermosensitive hydrogel ameliorate atopic dermatitis by mitigating keratinocyte mitochondrial damage through activating the Wnt/β-catenin pathway. International Immunopharmacology. 2026;173:116297. DOI: 10.1016/j.intimp.2026.116297
5. Kim JW, Lee HJ, Chang PS, et al. Hypoxic conditioning induced by CoCl2 enhanced the therapeutic effects of mesenchymal stem cell-derived exosomes on oxazolone-induced atopic dermatitis-like skin lesions in BALB/c mice. Molecular Immunology. 2026;189:153-162. DOI: 10.1016/j.molimm.2025.12.008
6. Cho BS, Lee JH, Shin KO, et al. Consistent functional properties of MSC-exosomes from different batches revealed by comparative multi-omics, bioinformatics and functional tests. Stem Cell Research and Therapy. 2026. DOI: 10.1186/s13287-026-05104-3